Clinical trial demonstrates inhaled treprostinil reduces FVC decline in patients with idiopathic pulmonary fibrosis, suggesting a promising treatment option.
In patients with IPF, inhaled treprostinil was associated with a smaller decline in FVC and fewer clinical-worsening events than placebo over a period of 52 weeks. (Funded by United Therapeutics; TETON-2 ClinicalTrials.gov number, NCT05255991.).
No takes yet. Share an insight, caveat, or question.
Nathan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: